Balloon Pulmonary Valvuloplasty in India and UAE | Complete Patient Guide

• ELIGIBLE PATIENTS:

• Congenital pulmonary valve stenosis with a peak Doppler gradient ≥ 40 mmHg on TTE (ACC/AHA Class I indication)

• Symptomatic patients (exertional dyspnea, syncope, chest pain, reduced exercise tolerance) at any gradient above 30 mmHg

• Asymptomatic patients with a peak gradient ≥ 50 mmHg or evidence of progressive right ventricular hypertrophy on CMR or ECG

• Pediatric patients (including neonates with critical pulmonary stenosis) and adults up to any age with suitable valve morphology

• Patients with concurrent patent foramen ovale (PFO) or atrial septal defect (ASD) where elevated RV pressure is driving right-to-left shunting

• Post-surgical residual pulmonary stenosis with hemodynamically significant re-stenosis

• REQUIRED DIAGNOSTIC WORK-UP:

• Transthoracic Echocardiography (TTE) with continuous-wave Doppler: primary modality for gradient quantification, RV size, and systolic function

• Transesophageal Echocardiography (TEE) or Intracardiac Echocardiography (ICE): detailed valve morphology and guidance during intervention

• Cardiac MRI (CMR): RV volumetry, ejection fraction, and fibrosis assessment in complex cases

• Right Heart Catheterization: definitive measurement of peak-to-peak and mean transvalvular gradients, RV and pulmonary artery pressures

• 12-Lead ECG: assessment for RV strain pattern (right axis deviation, R-wave dominance in V1)

• Chest X-Ray: post-stenotic pulmonary artery dilatation, cardiac silhouette

• Complete Blood Count (CBC), Renal Function Tests, Coagulation Profile (PT/INR, aPTT): pre-procedural safety screening

• Oxygen saturation at rest and on exercise (6-minute walk test): functional capacity baseline

• CONTRAINDICATIONS:

• Severe pulmonary valve dysplasia with markedly thickened, irregular, non-domed leaflets (surgical valvotomy or Ross procedure preferred)

• Isolated infundibular (subvalvular) stenosis without valvular component

• Supravalvular pulmonary artery stenosis (branch PA stenosis requires stenting or surgery)

• Active infective endocarditis involving the pulmonary valve

• Severe pulmonary regurgitation already present (BPV will worsen regurgitation)

• Uncorrectable coagulopathy or active systemic infection

• Anatomy precluding femoral venous access (alternative: internal jugular or transhepatic approach in selected cases)

STANDARD BALLOON PULMONARY VALVULOPLASTY (PRIMARY APPROACH): The conventional technique uses a single Inoue-style or dedicated pulmonary valvuloplasty balloon catheter (Tyshak II or Z-Med series). Under biplane fluoroscopic guidance, venous access is secured via the femoral vein using a 7–9 French sheath. A multipurpose or right Judkins catheter is advanced through the right atrium, across the tricuspid valve, through the RV, and positioned across the pulmonic valve into the distal pulmonary artery. A stiff exchange-length guidewire (e.g., Amplatz Super Stiff) is parked in the left pulmonary artery. The valvuloplasty balloon—sized to a balloon-to-annulus ratio (BAR) of 1.2–1.4:1, the critical determinant of efficacy and complication risk—is advanced over the wire, centered across the stenotic valve, and inflated rapidly to obliterate the fluoroscopic waist created by the obstructing leaflets. The balloon is then rapidly deflated and withdrawn. Immediate post-dilation hemodynamics and echocardiography confirm the residual gradient. A successful result is defined as a post-procedural peak gradient below 25–30 mmHg or a reduction of ≥ 50% from baseline.

DOUBLE-BALLOON TECHNIQUE: For large pulmonary annuli (typically > 20–22 mm in adults and older adolescents), the single-balloon approach may be limited by available balloon diameters. The double-balloon technique employs two balloons advanced simultaneously via bilateral femoral venous access, with their combined effective diameter calculated using the Yeager formula to achieve the optimal BAR. This approach allows treatment of annuli up to 30 mm and is associated with superior gradient reduction and lower residual stenosis compared to single-balloon dilation in large adults.

CUTTING BALLOON AND HIGH-PRESSURE BALLOON FOR RESTENOSIS: In patients presenting with restenosis following prior BPV or surgical valvotomy—where leaflet fibrosis and calcification reduce compliance—standard low-pressure balloons may be insufficient. Cutting balloons (Flextome, Boston Scientific) carry 3–4 atherotomes that score the resistant leaflet tissue, enabling effective commissurotomy at lower inflation pressures with reduced risk of annular trauma. High-pressure non-compliant balloons (up to 18–22 atm) are an alternative in calcified valves.

PULMONARY VALVE STENTING (TRANSCATHETER PULMONARY VALVE IMPLANTATION / TPVI): In patients with dysplastic pulmonary valves unsuitable for BPV alone, severe post-BPV pulmonary regurgitation causing hemodynamic compromise, or conduit-related RVOT obstruction (e.g., following tetralogy of Fallot repair), Transcatheter Pulmonary Valve Implantation (TPVI) using the Melody valve (Medtronic) or the SAPIEN XT/3 valve (Edwards Lifesciences) is the advanced catheter-based alternative to surgical pulmonary valve replacement. This procedure is performed in specialized hybrid cath-lab/OR suites available at premier cardiac centers in India and the UAE.

INTRACARDIAC ECHOCARDIOGRAPHY (ICE) GUIDANCE: Lead centers in Mumbai, Chennai, Delhi, Dubai, and Abu Dhabi integrate real-time ICE (AcuNav catheter, Siemens ACUSON X300) into the BPV procedure to permit precise balloon sizing, confirm wire position, monitor for immediate pericardial effusion, and assess post-dilation valve competence—reducing reliance on general anesthesia and TEE.

SEDATION PROTOCOLS: Adults and cooperative older children typically undergo BPV under conscious sedation (midazolam + fentanyl) or light procedural anesthesia with propofol infusion, avoiding the risks of general anesthesia. Neonates, infants, and young children require general anesthesia with full hemodynamic monitoring.

PHASE 1 — PRE-ARRIVAL & REMOTE CONSULTATION (2–4 weeks before travel):

• Patient submits medical records (echocardiography reports, CMR, prior cath data, ECG, blood work) to GAF Healthcare's clinical team via the secure online portal.

• A GAF-affiliated senior interventional cardiologist reviews the case and issues a formal treatment opinion within 48–72 hours, including procedure recommendation, balloon sizing estimation, and risk stratification.

• GAF coordinates e-Medical Visa (India) or UAE entry visa processing; travel and accommodation booking is initiated for patient and one attendant.

PHASE 2 — ARRIVAL & PRE-PROCEDURAL ASSESSMENT (Day 1–2):

• Airport pickup by GAF's dedicated medical concierge team; transfer to partner hospital or pre-arranged serviced apartment.

• Day 1: Hospital admission, clinical assessment by the interventional cardiology team, repeat TTE to confirm current gradients and RV function, baseline ECG, chest X-ray.

• Day 2 (if not done Day 1): Right heart catheterization (diagnostic) under local anesthesia to confirm hemodynamic severity; finalize balloon sizing using annulus measurement from TTE/CMR; anesthesia pre-assessment; consent process with translator present if needed.

• Pre-procedural medications: antiplatelet therapy (aspirin 75–100 mg if not already prescribed), prophylactic low-molecular-weight heparin in selected high-risk patients.

PHASE 3 — THE PROCEDURE (Day 2 or Day 3; duration: 60–120 minutes):

• Patient transferred to biplane cardiac catheterization laboratory; ECG, pulse oximetry, and invasive arterial pressure monitoring established.

• Conscious sedation or general anesthesia administered per pre-agreed protocol.

• Right femoral vein accessed under ultrasound guidance; 8 French sheath inserted.

• Diagnostic right heart catheterization performed: RV and PA pressures recorded, oxygen saturations measured, Fick cardiac output calculated.

• Stiff guidewire advanced into the distal left pulmonary artery.

• Valvuloplasty balloon (sized to BAR 1.2–1.4:1) advanced across the stenotic pulmonary valve under fluoroscopic and ICE guidance.

• Rapid inflation–deflation sequence (3–5 seconds per inflation) performed 2–3 times until the fluoroscopic waist is abolished.

• Immediate post-dilation hemodynamics recorded; residual gradient < 25 mmHg confirms technical success.

• Sheath removed; femoral access site compressed manually or with closure device; sterile dressing applied.

PHASE 4 — IMMEDIATE POST-PROCEDURAL RECOVERY (Day 3–4):

• Patient monitored in cardiac recovery unit for 4–6 hours: ECG telemetry, repeat TTE at 24 hours to document gradient reduction and rule out pericardial effusion.

• Bed rest for 6 hours post-procedure; ambulation commenced the same evening.

• Oral hydration resumed within 2 hours; regular diet by Day 3 morning.

• Discharge criteria: stable hemodynamics, residual gradient ≤ 30 mmHg on TTE, no arrhythmia on telemetry, access site intact.

• Most patients are discharged on Day 3 or Day 4 post-admission.

PHASE 5 — IN-COUNTRY RECOVERY BEFORE DEPARTURE (Days 4–10):

• Patient stays in partner serviced apartment with GAF concierge support; daily telephone check-in with the cardiac team.

• Mild activity (walking) encouraged from Day 3; strenuous activity (lifting > 5 kg, vigorous exercise) restricted for 2 weeks.

• No driving for 48 hours post-procedure; no heavy lifting for 1 week.

• Discharge medications typically include aspirin 75 mg for 1–3 months and, in patients with residual RV dysfunction, guideline-directed doses of loop diuretics (furosemide) or beta-blockers as clinically indicated.

PHASE 6 — FIT-TO-FLY ASSESSMENT (Day 7–10):

• Outpatient follow-up TTE and clinical review; if the residual gradient is stable and there are no complications, the cardiologist issues a fit-to-fly certificate.

• For most uncomplicated cases, international air travel is cleared at 7–10 days post-procedure.

• GAF Healthcare provides a complete digital discharge summary, imaging CDs/USB, and procedure report for the patient's home cardiologist.

PHASE 7 — LONG-TERM FOLLOW-UP:

• TTE recommended at 1 month, 6 months, and annually thereafter.

• Re-stenosis rate is approximately 5–10% at 5 years in pediatric patients with rapid somatic growth and approximately 3–5% in adults.

• GAF Healthcare facilitates remote follow-up teleconsultation with the treating cardiologist at 1 and 6 months post-discharge.